Advanced

Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate

Brattström, L; Stavenow, L.; Galvard, H LU ; Nilsson-Ehle, P LU ; Berntorp, E LU ; Jerntorp, P; Elmståhl, S LU and Pessah-Rasmussen, H LU (1990) In Scandinavian Journal of Clinical & Laboratory Investigation 50(8). p.873-877
Abstract

We have previously observed that pyridoxine treatment reduced plasma total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol concentrations and increased antithrombin III (AT III) activity in atherosclerotic patients with subnormal plasma pyridoxal 5-phosphate (PLP) levels. In order to confirm these results, we selected 17 males with low plasma PLP levels from a group of 122 80-year-old males in whom PLP has been determined. After supplementation with 120 mg of pyridoxine per day for 8 weeks their mean plasma TC and LDL cholesterol concentrations were decreased by 10% (p less than 0.01) and 17% (p less than 0.001), respectively. There was no effect on high-density lipoprotein cholesterol and triglycerides but plasma AT III... (More)

We have previously observed that pyridoxine treatment reduced plasma total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol concentrations and increased antithrombin III (AT III) activity in atherosclerotic patients with subnormal plasma pyridoxal 5-phosphate (PLP) levels. In order to confirm these results, we selected 17 males with low plasma PLP levels from a group of 122 80-year-old males in whom PLP has been determined. After supplementation with 120 mg of pyridoxine per day for 8 weeks their mean plasma TC and LDL cholesterol concentrations were decreased by 10% (p less than 0.01) and 17% (p less than 0.001), respectively. There was no effect on high-density lipoprotein cholesterol and triglycerides but plasma AT III activity was increased by 6% (p less than 0.05). The mechanism by which pyridoxine acts is unclear but it is hypothesized that pyridoxine-derived PLP may enhance the catabolism of LDL and the activity of AT III by inhibiting their glycosylation.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cholesterol, pyridoxal 5-phosphate, antithrombin III, pyridoxine, low-density lipoproteins
in
Scandinavian Journal of Clinical & Laboratory Investigation
volume
50
issue
8
pages
5 pages
publisher
Informa Healthcare
external identifiers
  • pmid:2084825
  • scopus:0025650379
ISSN
1502-7686
DOI
10.3109/00365519009104955
language
English
LU publication?
yes
id
92f022b1-5493-46fc-b109-f9ff0c57dbab (old id 1105453)
date added to LUP
2008-08-05 15:42:07
date last changed
2017-09-12 13:23:18
@article{92f022b1-5493-46fc-b109-f9ff0c57dbab,
  abstract     = {<p>We have previously observed that pyridoxine treatment reduced plasma total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol concentrations and increased antithrombin III (AT III) activity in atherosclerotic patients with subnormal plasma pyridoxal 5-phosphate (PLP) levels. In order to confirm these results, we selected 17 males with low plasma PLP levels from a group of 122 80-year-old males in whom PLP has been determined. After supplementation with 120 mg of pyridoxine per day for 8 weeks their mean plasma TC and LDL cholesterol concentrations were decreased by 10% (p less than 0.01) and 17% (p less than 0.001), respectively. There was no effect on high-density lipoprotein cholesterol and triglycerides but plasma AT III activity was increased by 6% (p less than 0.05). The mechanism by which pyridoxine acts is unclear but it is hypothesized that pyridoxine-derived PLP may enhance the catabolism of LDL and the activity of AT III by inhibiting their glycosylation.</p>},
  author       = {Brattström, L and Stavenow, L. and Galvard, H and Nilsson-Ehle, P and Berntorp, E and Jerntorp, P and Elmståhl, S and Pessah-Rasmussen, H},
  issn         = {1502-7686},
  keyword      = {cholesterol,pyridoxal 5-phosphate,antithrombin III,pyridoxine,low-density lipoproteins},
  language     = {eng},
  number       = {8},
  pages        = {873--877},
  publisher    = {Informa Healthcare},
  series       = {Scandinavian Journal of Clinical & Laboratory Investigation},
  title        = {Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate},
  url          = {http://dx.doi.org/10.3109/00365519009104955},
  volume       = {50},
  year         = {1990},
}